Please wait while the transcript is being prepared...
0:00
Hello, I am Fernando de Mora
Professor of Pharmacology at
a fairly big Spanish
University called
Universidad Autónoma de
Barcelona, a public University.
I have been asked to
deliver a talk on
biosimilars and try to
convey the message that volume
meets costs in that case.
0:20
So the message that I want to
deliver would be biosimilar,
in fact, is a
biological medicine.
that shares the active substance
with an original biologic.
It is administered
by the same route,
at the same dose, and for
the same indications.
What I want to do
is I want to try to
help you understand why
can we conclude this?
0:43
We will address this issue
by discussing four topics.
I will start with
explaining what is
a biologic medicine vs
non-biological medicine.
0:54
Well, let's assume
for the purpose of
this talk that a biologic
is just a medicine,
obtained from a living organism.
If we go to legal definitions,
that is far more complicated.
But we can consider
that whenever
a living organism is
producing the medicine,
it is a biologic medicine.
For instance, insulin
from the pancreas.
That was at that time
a biologic medicines.
But we can also obtain
biologic medicines
from human sources.
For instance, factor VIII.
If I get the blood,
extract blood from
healthy volunteers,
I can isolate the
coagulation factor VIII
and use it in
hemophilic patients.
Now, is there an
alternative source of
this human factor
VIII? Indeed there is.
